(Q43919567)

English

Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene

scientific article published on 3 December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Mycobacterium tuberculosis

0 references

1 reference

based on heuristic

inferred from title

author name string

Shi Changhong

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Zhang Hai

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Wang Limei

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

An Jiaze

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Xi Li

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Zhang Tingfen

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Xu Zhikai

7

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Zhao Yong

8

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

publication date

3 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

89

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

54-61

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Drug-resistant tuberculosis: what do we do now?

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Impact of HIV infection on tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Variation in protection by BCG: implications of and for heterologous immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Current strategies in TB immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Long term efficacy of DOTS regimens for tuberculosis: systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Protection against tuberculosis by a plasmid DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Therapy of tuberculosis in mice by DNA vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Expression of the recombinant fusion protein CP15-23 of Cryptosporidium parvum and its protective test

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter?

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

CD8+ T cells in tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

CD4(+) T cells are required for the development of cytotoxic CD8(+) T cells during Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Vaccination against tuberculosis by DNA injection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Selective activation of resting human gamma delta T lymphocytes by interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Vaccine adjuvant: it makes the difference

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Pulmonary necrosis resulting from DNA vaccination against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2008.09.005

7 January 2021

Identifiers

10.1016/J.TUBE.2008.09.005

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43919567&oldid=2104392964"